Abstract
This study explores the application of deep proteomic profiling to extract disease-specific features from urine. Early detection of cancer and other chronic disorders is crucial for better outcomes, but traditional diagnostics as well as emerging genomic-based diagnostics are expensive and invasive. Our research reveals that a select group of urinary proteins can accurately detect early-stage diseases with high sensitivity, surpassing current tests. While urine-based protein panels could offer cost-effective and accurate alternatives to current screening methods, kidney factors and blood urine barrier pathologies could pose significant challenges. New diagnostic technologies may emerge because of these findings, ushering in an era of early detection for cancer and chronic diseases.
One-Sentence Summary Urine-based protein panels show distinct patterns in early disease detection, promising opportunities for advancing diagnostic tests
Competing Interest Statement
The authors have been employed and/or hold shares in Novelna Inc.
Funding Statement
This study was funded by Novelna Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Ukraine Association of Biobank waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.